Patients are increasingly presenting with “rare cancers,” more narrowly defined by their molecular characteristics, sometimes making the best course of treatment unclear. Today more than ever, oncologists need real-time decision support to help them provide the most effective treatments tailored to their patients’ unique biology and tumors.
Read more:
http://www.asco.org/ASCOv2/Practice+%26+Guidelines/Quality+Care/CancerLinQ+-+Building+a+Transformation+in+Cancer+Care?et_cid=29389283&et_rid=463566871&linkid=LEARN+MORE